6-Isopropyl-tetralon-(1) | 60606-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6-Isopropyl-tetralon-(1)
• 英文别名: 6-Isopropyl-3,4-dihydro-1(2H)-naphthalenon；6-(Propan-2-yl)-3,4-dihydronaphthalen-1(2H)-one；6-propan-2-yl-3,4-dihydro-2H-naphthalen-1-one
• CAS: 60606-92-0
• 化学式: C₁₃H₁₆O
• mdl: MFCD11518733
• 分子量: 188.269
• InChiKey: QKJXUPWAONTKTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-Isopropyl-tetralon-(1) 生成 2,10a-Dimethyl-7-isopropyl-1,9,10,10a-tetrahydro-3(2H)-phenanthron
  参考文献：
  名称：

  Novel C19 trienes from abietic acid in fluorosulfonic acid

  摘要：

  DOI：

  10.1021/jo00422a007
• 作为产物：
  描述：

  2-(3-异丙基苯基)乙基溴 生成 6-Isopropyl-tetralon-(1)
  参考文献：
  名称：

  The Total Synthesis of dl-Dehydroabietic Acid

  摘要：

  DOI：

  10.1021/ja00861a031

文献信息

• Fused Pyrazoles as FGFR Inhibitors
  申请人：Incyte Corporation

  公开号：US20140171405A1

  公开（公告）日：2014-06-19

  The present invention relates to fused pyrazole derivatives, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

  本发明涉及融合吡唑衍生物，以及包括这些衍生物的药物组合物，这些衍生物是一种或多种FGFR酶的抑制剂，并且在治疗FGFR相关疾病如癌症方面具有用处。
• Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
  申请人：Silverback Therapeutics, Inc.

  公开号：US20200113912A1

  公开（公告）日：2020-04-16

  Methods and conjugates are disclosed for alleviating toxicity(ies) associated with administration of immune-stimulatory conjugates, and in particular for alleviating toxicity(ies) associated with intravenous administration of such conjugates.

  本发明揭示了用于减轻与免疫刺激共轭物的给药相关的毒性的方法和共轭物，并且特别用于减轻与静脉给药这类共轭物相关的毒性。
• FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Kuduk Scott D.

  公开号：US20110201607A1

  公开（公告）日：2011-08-18

  The present invention is directed to fused heterocyclic compounds of formula (I): which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式(I)的融合杂环化合物，其为M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗M1受体介导的疾病中的使用。
• BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF
  申请人：Silverback Therapeutics, Inc.

  公开号：EP3949969A2

  公开（公告）日：2022-02-09

  Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.

  本文公开了用于治疗癌症等疾病的苯并氮杂卓化合物、共轭物和药物组合物。所公开的苯并氮杂卓化合物主要用于治疗癌症和调节 TLR8。此外，本文还描述了与抗体构建体结合的苯并氮杂卓化合物。
• Benzazepine compounds, conjugates, and uses thereof
  申请人：SILVERBACK THERAPEUTICS, INC.

  公开号：US10239862B2

  公开（公告）日：2019-03-26

  Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.

  本文公开了用于治疗癌症等疾病的苯并氮杂卓化合物、共轭物和药物组合物。所公开的苯并氮杂卓化合物主要用于治疗癌症和调节 TLR8。此外，本文还描述了与抗体构建体结合的苯并氮杂卓化合物。